iSpecimen Inc. - Common Stock (ISPC)

That’s the story unfolding right now around iSpecimen Inc. (NASDAQ: ISPC), a microcap life sciences company that just made one of the boldest capital strategy announcements in recent memory. On Wednesday evening—after the market closed—iSpecimen unveiled its plan to establish a $200 million digital treasury focused on capital preservation, liquidity, and long-term growth.

WOBURN, MA / ACCESS Newswire / August 8, 2025 / Occasionally, the market reacts in ways that don't immediately align with the news. That seems to be the case right now with iSpecimen Inc. (NASDAQ:ISPC), following a major strategic announcement that arrived after Wednesday's close.

WOBURN, MA / ACCESS Newswire / August 8, 2025 / Sometimes the market delivers gifts-but only to those paying attention. That's the story unfolding right now around iSpecimen Inc. (NASDAQ:ISPC), a microcap life sciences company that just made one of the boldest capital strategy announcements in recent memory. On Tuesday evening-after the market closed-iSpecimen unveiled its plan to establish a $200 million digital treasury focused on capital preservation, liquidity, and long-term growth.

Sometimes, the market gets it wrong. And when it does—when there’s a glaring disconnect between price and reality—savvy investors don’t just notice. They act.

WOBURN, Mass., Aug. 04, 2025 (GLOBE NEWSWIRE) -- iSpecimen Inc. (Nasdaq: ISPC) (“iSpecimen” or the “Company”), an online global marketplace that connects scientists requiring biospecimens for medical research with a network of healthcare specimen providers, today announced that it closed its previously announced private placement pursuant to a securities purchase agreement with accredited investors for aggregate gross proceeds of approximately $1.75 million, before deducting fees to the placement agent and other offering expenses payable by the Company. The Company intends to use the net proceeds from the offering to pay $500,000 for marketing and advertising services to be provided by IR Agency LLC, and the remainder for working capital and general corporate purposes.

WOBURN, Mass., July 31, 2025 (GLOBE NEWSWIRE) -- iSpecimen Inc. (Nasdaq: ISPC) (“iSpecimen” or the “Company”), an online global marketplace that connects scientists requiring biospecimens for medical research with a network of healthcare specimen providers, today announced that it entered into a securities purchase agreement with accredited investors for aggregate gross proceeds of approximately $1.75 million, before deducting fees to the placement agent and other offering expenses payable by the Company. The Company intends to use the net proceeds from the offering to pay $500,000 for marketing and advertising services to be provided by IR Agency LLC, and the remainder for working capital and general corporate purposes.

WOBURN, Mass., July 28, 2025 (GLOBE NEWSWIRE) -- This press release corrects a version issued on July 25, 2025 that incorrectly listed KCSA Strategic Communications as iSpecimen’s investor relations contact. KCSA is not currently affiliated with iSpecimen Inc. and was mistakenly included in the prior release. The corrected release is below in its entirety.

WOBURN, Mass., July 28, 2025 (GLOBE NEWSWIRE) -- This press release corrects the version issued on July 24, 2025 that incorrectly listed KCSA Strategic Communications as iSpecimen’s investor relations contact. KCSA is not currently affiliated with iSpecimen Inc. and was mistakenly included in the prior release. The corrected release is below in its entirety.

WOBURN, Mass., July 25, 2025 (GLOBE NEWSWIRE) -- iSpecimen Inc. (Nasdaq: ISPC) (“iSpecimen” or the “Company”), an online global marketplace that connects scientists requiring biospecimens for medical research with a network of healthcare specimen providers, announced today the closing of its previously announced underwritten public offering of 5,714,283 shares of its common stock (or pre-funded warrants to purchase common stock in lieu thereof) at a public offering price of $0.70 per share (the “Offering”). The aggregate gross proceeds to the Company from the Offering was approximately $4 million, before deducting underwriting discounts and commissions and other offering expenses.

WOBURN, Mass., July 24, 2025 (GLOBE NEWSWIRE) -- iSpecimen Inc. (Nasdaq: ISPC) (“iSpecimen” or the “Company”), an online global marketplace that connects scientists requiring biospecimens for medical research with a network of healthcare specimen providers, announced today the pricing of an underwritten public offering of 5,714,283 shares of its common stock (or pre-funded warrants to purchase common stock in lieu thereof) at a public offering price of $0.70 per share (the “Offering”). The aggregate gross proceeds to the Company from the Offering are expected to be approximately $4 million, before deducting underwriting discounts and commissions and other estimated offering expenses. The Offering is expected to close on July 25, 2025, subject to the satisfaction of customary closing conditions.

On Thursday morning, iSpecimen Inc. (NASDAQ: ISPC) attracted significant investor attention with a 48% premarket jump to $6.60. While momentum eased after the open, ISPC bulls remained in control, ending the day with an impressive 11% gain and trading volume over ten times its usual average. Incidentally, that jump was well-deserved.

The premarket surge in iSpecimen Inc. (NASDAQ: ISPC) on Thursday caught the attention of many, with the stock leaping 48% to $6.60 at the early morning’s peak. While it moderated slightly after the opening bell, iSpecimen maintained momentum, closing up over 11% amid, a trading volume more than ten times its daily average.

The premarket surge in iSpecimen Inc. (NASDAQ: ISPC) on Thursday may have surprised some investors, but certainly not all. Those familiar with this innovative company can quickly point to an evidence-based case for why ISPC stock jumped 48% to $6.60. While it retreated to start the regular session, the bulls remained firmly in control of the trading-day narrative, with shares closing Thursday higher by over 11% on over 10x average volume.

RJD Green Inc. (OTC: RJDG) captured significant investor attention, leading to a substantial stock gain of 29.5% on June 5, 2024. The trading volume surged to nine times the average daily volume. The company announced that its business unit, Silex Holdings Inc., achieved its highest monthly revenue since its establishment in June 2006. In May, Silex Holdings, Inc., a division of RJD Green, recorded $865,730 in revenues and a net operating profit of $242,404 . For context, the average annual revenue from Silex over the past two years was $4,800,000, with May 2024 revenues accounting for 18.1% of the annual income in 2023.